2023 EBMT-EHA: Encouraging initial safety and efficacy data for point-of-care manufactured GLPG5201 CAR-T in rrCLL presented
“We were very pleased to present strong initial data from the ongoing Phase 1/2 study of our fresh CD19 CAR-T candidate manufactured at point-of-care. This marks an important milestone in our journey to transform the lives of patients with severe blood cancers, including patients with RT, through the acceleration of innovation and breakthrough science”, said Dr. Paul Stoffels1, CEO of Galapagos. “We look forward to reporting Phase 1 topline data around mid-year.”
Share:
More News
“The initial efficacy data from the Part C studies are consistent with the encouraging efficacy signals we previously reported for Parts A and B of THIO-101, including an 88% disease control rate in third-line NSCLC patients. This measure of efficacy is close to triple the reported outcome for standard-of-care chemotherapy
“Patients with non-muscle invasive bladder cancer continue to face a significant risk of disease recurrence despite available treatment options,” said Mark Schoenberg, M.D., Chief Medical Officer of UroGen. “UGN-501 is an investigational next-generation oncolytic virus designed to selectively destroy tumor cells while generating an anti-tumor immune response. FDA clearance of
“Whitehawk has established strong expertise in ADC technology and oncology drug development,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “This collaboration further expands the application of Biocytogen’s fully human bispecific antibodies in ADC development. We look forward to supporting the efficient advancement of multiple programs by contributing high-quality
Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said: “The AZUR-1 results support the potential for dostarlimab to transform treatment for dMMR/MSI-H locally advanced rectal cancer. For many patients today, rectal cancer treatment comes with the tolerability burden and lasting impacts from chemotherapy, radiation and surgery. These data